Tue, Oct 21, 2014, 4:48 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

3D Systems Corporation Message Board

mgm2020 940 posts  |  Last Activity: 1 hour 37 minutes ago Member since: Mar 3, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mgm2020 mgm2020 1 hour 37 minutes ago Flag

    Hey w4k---we all DO know that it's coming, BUT, the wild card here is the breakthrough designation and priority review. I'm pegging this at a minimum of $36 prior to approval, so at least a $10 increase from here.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 2 hours 19 minutes ago Flag

    The feeling is mutual for brainless and pointless replies. You DO know that Cramer spotlighted ACAD and ISIS a few weeks ago as 2 of the most enticing biotech buyout candidates because of their pipeline and prospects?

    Sentiment: Strong Buy

  • I don't think so. And don't believe for a second that this thought is not in EVERYONE'S mind that holds ACAD. What is the purpose of your reply exactly?

    Sentiment: Strong Buy

  • Someone or some fund wants in here. 274K shares at the bid right now. Over half a million worth of IDRA-----that will be worth much more in a few months. The market is turning-----and so will IDRA.

    Sentiment: Strong Buy

  • And that will help propel the stock to new highs when they begin to come to their senses. Upgraded by Zack's to #1 STRONG BUY, Cowen, and Bank of America with an average price target of $26. And THAT is ONLY THE BEGINNING! With a GIGAWATT expansion into China and the lowest production and installation cost in the industry it's just a matter of (a little) time before they take more and more market share. Add another revenue stabilizing and generating yieldco and this stock could double in the next 2 years.

    Sentiment: Strong Buy

  • Reply to

    Question about psoriasis data

    by timehusk Oct 20, 2014 6:34 AM
    mgm2020 mgm2020 Oct 20, 2014 10:15 AM Flag

    According to Jim Baker at IDRA investor relations the company wants to present the data at an appropriate medical conference, but not until it has been totally evaluated, peer-reviewed, and most likely published to coincide with the conference. The bigger question, and the more important question for shareholders is, how could they have decided to escalate the dose of IMO-8400 up to 4 TIMES the .6 dosage for WM without knowing if it was effective or safe? And the answer is----they couldn't! So---I really think the psoriasis data is immaterial as far as a revenue-generating therapeutic is concerned. WM, the myositis, GVH, and ALL of the other autoimmune diseases are where the motherlode is. And we're going to be well on our way towards the end of this year and into and through 2015.

    Sentiment: Strong Buy

  • This will certainly help make the winter go faster. First---NDA. Then 60 day letter of acceptance, breakthrough designation and priority review. Then-----approval by JUNE?? The chances of ACAD being bought increase dramatically following the 60 day letter and with a priority review. What big pharma company wouldn't want to get their hands on Nuplazid and it's myriad of applications. And doctors, patients, and their families who have to deal with the effects of Parkinson's psychosis will be clamoring for this drug. While their will most likely still be some short-lived dips in the stock price prior to the acceptance, this is one stock you do not want to reduce your holdings in, and if possible, pick up more on the dips. $35 minimum by approval and likely higher and any buyout will be in the $50+ range.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Oct 18, 2014 12:42 PM Flag

    When I spoke with him about 2 weeks ago I got the same impression and am extremely optimistic about 2015 as a transitional AND TRANSFORMATIONAL year for IDRA with multiple trials in both platforms underway. The news is starting to flow and the stock will not be presenting this opportunity for long.

    Sentiment: Strong Buy

  • SunEdison shares rally after upgrade
    11:56a ET October 17, 2014 (MarketWatch)

    SunEdison shares rally after upgrade
    By Claudia Assis, MarketWatch
    SAN FRANCISCO (MarketWatch) -- Shares of SunEdison Inc. soared nearly 10% on Friday after analysts at Cowen & Co. upgraded the stock to outperform, saying the solar developer has become even more attractive following the recent selloff in the solar sector.
    SunEdison (SUNE), whose main business is building solar-power plants in the U.S., is a lower risk stock than its peers, and shares should be trading in the low $20s "at a minimum," the Cowen analysts said.
    Cowen has a price target of $24 on SunEdison's stock, which represents 40% upside from Friday's trading.
    The company has "minimal" exposure to Japan, where recently utilities have restricted new solar plants from accessing their grids. It's also a pioneer in the spinoffs known in the industry as "yieldcos", which drive down the cost of its capital, the analysts said.
    SunEdison said last month it plans on a second "yieldco," this time bundling solar projects and assets in emerging markets. That would follow the initial public offering of SunEdison's spinoff TerraForm Power Inc. (TERP) in July.
    At current price levels, the stock "appears to have little baked in its valuation for additional YieldCos or longer term distributions," the Cowen analysts said.

    Sentiment: Strong Buy

  • And looing to BUY here expecting a rise----which IS coming.

    Sentiment: Strong Buy

  • I added 5000 to bring my total to 50,000. Anyone who is concerned about today shouldn't be. IDRA has climbed over 15% IN THE LAST 3 DAYS!! Looking at a lot of small bio's today on my screen that are red, although not by much. There seems to be a lot going back into the large and mid-caps today with the Russell taking a little breather. This will change as the small and micro-caps move up again. IDRA is one of the most compelling small-cap bio's out there with an amazing amount of potential. We will see that potential turn into actuality when the WM data is announced and the .6 psoriasis data is released. The news is coming and it is best to be prepared for the big move back up.

    Sentiment: Strong Buy

  • Reply to

    not a good day to be short

    by oilup12345 Oct 17, 2014 7:51 AM
    mgm2020 mgm2020 Oct 17, 2014 9:18 AM Flag

    Don't think so----stock will head back up and pass $3 by the time we get the WM data-----and maybe much higher. I think we'll see a logarithmic move up with bigger and bigger increases as the price rises. Shorts should exit here as the Russell is springing to life again also.

    Sentiment: Strong Buy

  • Reply to

    cramer mentioned ACAD today

    by iznogizno Oct 16, 2014 6:54 PM
    mgm2020 mgm2020 Oct 17, 2014 9:12 AM Flag

    $35 by June 1st of 2015. That's a 40% move from here---and that's my MINIMUM price target. With a breakthrough designation and a priority review then I raise my target to $50 by June 1st. Most biotech's will rise an average of 90-110% between the time they file their NDA and their PDUFA. And with ACAD having a corner on their market that's practically a lock.

    Sentiment: Strong Buy

  • It seems the shorts can't read since there have been at least 2 upgrades of SUNE in the last 3 days with a price target of $28 from BOA and more positive press on solar in the last week than there has been in a while. When you want to be the GLOBAL LEADER in solar, you have to invest to ensure that. THIS is what they are doing. Multiple upgrades along with major expansion including a large presence in China does NOT make for a good investment strategy for the 23% that are short here. SUNE is definitely NOT going down anytime soon, and if they do not cover they will watch your profits disappear and their losses mount. Fine with me because there are PLENTY of buyers eager to get in quickly here and ride the stock MUCH higher.

    Sentiment: Strong Buy

  • Reply to

    WFR is DEBT DRUNK

    by jazyje Oct 17, 2014 8:53 AM
    mgm2020 mgm2020 Oct 17, 2014 9:01 AM Flag

    I guess you can't read since there have been at least 2 upgrades of SUNE in the last 3 days with a price target of $28 from BOA. But you MUST be doing much more research than them to be posting the same thing over and over and over........If you want to be the GLOBAL LEADER in solar, you have to invest to ensure that. THIS is what they are doing. Multiple upgrades along with major expansion including a large presence in China does NOT make for a good investment strategy for the 23% that are short here. SUNE is definitely NOT going down anytime soon, and if they(you) do not cover you will watch your profits disappear and your losses mount.

    Sentiment: Strong Buy

  • Rapid expansion---into CHINA---new polysilicon plant with the lowest cost in the world----and MORE! What a time to buy---still moving UP from the bottom.

    Sentiment: Strong Buy

  • Bank Of America Sees Solar As 'Prime Buying Opportunity'
    1:06p ET October 16, 2014 (Benzinga) Print

    Bank of America issued an earnings preview on alternative energy companies Thursday. The firm saw a "prime buying opportunity" heading into earnings and the upcoming Solar Power International trade show.

    Analysts Krish Sankar and Andrew Hughes held the view that "solar stocks have been impacted more by de-risking and broader market concerns than by any underlying change in industry fundamentals."

    "With a number of industry and company specific catalysts also on the horizon...we see excellent buying opportunities heading into the industry’s biggest trade show (SPI Oct 20-23) as well as 3Q14 earnings season," according to Sankar.

    Sunedison Inc (NYSE: SUNE) - Buy, $28 price target.

    The company continued "to execute on pipeline growth. Further details on its distributed generation (DG) build out, and emerging market focused YieldCo could serve as a positive catalyst as well," according to the report.

    Sentiment: Strong Buy

  • EXPLODE HIGHER??? With the "pile on" mentality in the market---whether it is related to buying or selling, IDRA is going break out of impulse power and start hitting warp speed when the market and investors realize the data that is coming will double or triple the price of this stock in a matter of weeks. This has been one forgotten biotech for months but it held the bottom at around $2 and the buying is finally picking up. Watch for the move up to accelerate into news and data.

    Sentiment: Strong Buy

  • Their "articles" are totally worthless and their "ratings" are even worse. They base everything strictly on numbers and NEVER on forecasts or market movements or sentiment. When they finally say the rate SUNE as a buy the stock will already be $25/share!

    Sentiment: Strong Buy

  • The price of the stock ran up last time due to the early psoriasis data, which was simply a "proof of concept" trial, which also happened to show very positive results on a very LOW dose of IMO-8400. The Waldenstrom's trial is much more important and compelling than that, and the dosages are up to 8 times the psoriasis dose. The stock will run up in anticipation of the data and could challenge OR SURPASS the spring highs with positive data. That and the orphan disease applications and the 9200 trials beginning make IDRA a VERY interesting stock---especially at these ridiculous price levels.

    Sentiment: Strong Buy

DDD
43.38+1.30(+3.09%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.